ArticlePDF Available

Ability of Lactobacillus and Propionibacterium Strains to Remove Aflatoxin B 1 from the Chicken Duodenum

Authors:

Abstract and Figures

The ability of Lactobacillus rhamnosus strains GG and LC-705 to remove AFB1 from the intestinal luminal liquid medium has been tested in vivo using a chicken intestinal loop technique. In this study, the GG strain of L. rhamnosus decreased AFB1 concentration by 54% in the soluble fraction of the luminal fluid within 1 min. This strain was more efficient in binding AFB1 compared with L. rhamnosus strain LC-705 (P < 0.05) that removed 44% of AFBl under similar conditions. Accumulation of AFB1 into the intestinal tissue was also determined. There was a 74% reduction in the uptake of AFB1 by the intestinal tissue, in the presence of L. rhamnosus strain GG compared with 63% and 37% in the case of Propionibacterium freudenreichii ssp. shermanii JS and L. rhamnosus strain LC-705, respectively. The complexes formed in vitro between either L. rhamnosus strain GG or L. rhamnosus strain LC-705 and AFB1 were stable under the luminal conditions for a period of 1 h.
Content may be subject to copyright.
549
Journal of Food Protection, Vol. 63, No. 4, 2000, Pages 549–552
Copyright Q, International Association for Food Protection
Research Note
Ability of
Lactobacillus
and
Propionibacterium
Strains to
Remove Aflatoxin B
1
from the Chicken Duodenum
HANI EL-NEZAMI,
1
HANNU MYKKA
¨NEN,
2
PASI KANKAANPA
¨A
¨,
1
SEPPO SALMINEN,
1,3
AND
JORMA AHOKAS
1
*
1
Key Centre for Applied and Nutritional Toxicology, RMIT-University, GPO Box 2476V, Melbourne, Vic 3001, Australia;
2
Department of Clinical
Nutrition, University of Kuopio, P.O. Box 1627, 70211 Kuopio, Finland; and
3
Department of Biochemistry and Food Chemistry, University of Turku,
20014 Turku, Finland
MS 98-324: Received 11 December 1998/Accepted 7 July 1999
ABSTRACT
The ability of Lactobacillus rhamnosus strains GG and LC-705 to remove AFB
1
from the intestinal luminal liquid medium
has been tested in vivo using a chicken intestinal loop technique. In this study, the GG strain of L. rhamnosus decreased AFB
1
concentration by 54% in the soluble fraction of the luminal fluid within 1 min. This strain was more efficient in binding AFB
1
compared with L. rhamnosus strain LC-705 (P,0.05) that removed 44% of AFB
1
under similar conditions. Accumulation
of AFB
1
into the intestinal tissue was also determined. There was a 74% reduction in the uptake of AFB
1
by the intestinal
tissue, in the presence of L. rhamnosus strain GG compared with 63% and 37% in the case of Propionibacterium freudenreichii
ssp. shermanii JS and L. rhamnosus strain LC-705, respectively. The complexes formed in vitro between either L. rhamnosus
strain GG or L. rhamnosus strain LC-705 and AFB
1
were stable under the luminal conditions for a period of 1 h.
The occurrence of aflatoxin in feedstuff is common all
over the world (12). Aflatoxins have been detected as con-
taminants of crops before harvest, during harvesting and
drying, in storage, as well as after processing and manu-
facturing (3). Following ingestion of aflatoxin-contaminat-
ed feeds, accumulation of AFB
1
and aflatoxin M
1
into eggs
and milk has been reported (1, 10). Even low levels of
aflatoxins in feeds may result in decreased milk yield and
egg production by farm animals. In experimental animals
low levels of AFB
1
have been shown to be immunosup-
pressive and to possess mutagenic and teratogenic activity
causing cancer and liver damage (2, 9). Thus, chronic ex-
posure to aflatoxins may not only significantly alter food
production and farm animal productivity, but consumption
of aflatoxin-contaminated food commodities may also rep-
resent a health risk to the consumer. It is therefore important
to reduce and/or prevent human exposure by developing
practical and effective methods to detoxify aflatoxin-con-
taminated foods and feedstuffs.
AFB
1
appears to be absorbed rapidly from the small
intestine into mesenteric venous blood. Kumagai (8) in-
jected [
3
H]AFB
1
directly into the stomach and various sites
of the small intestine of rats and measured the radioactivity
in the bile 30 min later. He demonstrated that the site of
absorption was the small intestine; and the absorption was
most efficient from the duodenum.
* Author for correspondence. Tel: 161 3 992 52650; Fax: 161 3 9663
6087; E-mail: Toxicology@rmit.edu.au.
Present address: Department of Clinical Nutrition, University of Kuopio,
P.O. Box 1627, 70211 Kuopio, Finland.
Present address: Department of Biochemistry and Food Chemistry, Uni-
versity of Turku, 20014 Turku, Finland.
In an effort to develop a practical method for aflatoxin
detoxification, we have investigated the ability of selected
dairy strains of lactic acid bacteria to remove AFB
1
from
liquid media (4–6). Lactobacillus rhamnosus strains GG
and LC-705 removed a significantly greater amount of
AFB
1
, compared to other strains of either gram-positive or
gram-negative bacteria. The AFB
1
removal by these two
strains was a rapid process. The aims of the current study
were to investigate: (i) the ability of the selected strains to
bind AFB
1
under the conditions inside the duodenum; (ii)
the ability of the selected strains to influence AFB
1
uptake
by the duodenal tissue; and (iii) the stability of the complex
formed in vitro between these strains and AFB
1
under the
conditions inside the duodenum.
A strain of Propionibacterium freudenreichii ssp. sher-
manii JS was also included in this study.
MATERIALS AND METHODS
Bacterial strains and determination of bacterial concen-
tration. Bacteria used were L. rhamnosus strains GG (ATCC
53103) and LC-705 and P. freudenreichii ssp. shermanii JS. The
bacterial strains were obtained from Valio Ltd. (Helsinki, Finland)
as a freeze-dried powder. The concentration of lyophilizedbacteria
(number of bacteria/g of powder) was measured by flowcytometry
using a Coulter Electronics EPICS XL cytometer equipped with
an air-cooled 488 nm argon-ion laser operating at 15 mW. Via-
bility was assessed using the method described by Virta et al. (11).
In vivo binding assay. The University of Kuopio Animal
Ethics Committee approved experiments. One-week-old broiler
chicks (Vilppulan Hybrid Ltd., Vilppula, Finland) were used in
these experiments. The chicks were anesthetized by an intraperi-
toneal injection with 0.1 ml/100 g body weight of Mebunat so-
Downloaded from http://meridian.allenpress.com/jfp/article-pdf/63/4/549/2204379/0362-028x-63_4_549.pdf by Thailand user on 12 January 2023
J. Food Prot., Vol. 63, No. 4550 EL-NEZAMI ET AL.
TABLE 1. AFB
1
recovered from the intestinal tissue and luminal fluid of 1-week-old chicks after intraduodenal injection of AFB
1
with
or without bacteria
a
The concentration of AFB
1
6SD extracted from:
Group
Duodenal tissue
b
1 min 60 min
Soluble fraction
of luminal fluid
c
1 min 60 min
Bacterial pellet
c
1 min 60 min
LBGG
d
only
AFB
1
only
LBGG
d
1AFB
1
LC705
e
1AFB
1
PJS
f
1AFB
1
ND (5)
0.27 60.09 (5)
0.07 60.05 (3)
0.17 60.11 (2)
0.10 60.05 (5)
ND
g
(5)
ND (5)
ND (5)
ND (5)
ND (5)
ND (5)
1.04 60.36 (5)
0.48 60.15 (3)
0.58 60.10 (2)
0.67 60.13 (5)
ND (5)
0.05 60.01 (5)
ND (5)
0.08 60.06 (3)
0.13 60.02 (2)
ND (5)
ND (5)
0.76 60.04 (3)
0.54 60.10 (2)
0.55 60.11 (5)
ND (5)
ND (5)
1.38 60.16 (5)
1.07 60.12 (3)
1.24 60.06 (2)
a
Intraduodenal dose; 10
10
CFU 11.5 mg of AFB
1
in 0.5 ml of PBS. The original number of chickens per group was 5 but the number
of successful experiments used to obtain these data is indicated in brackets.
b
Concentration expressed as mg AFB
1
/g tissue.
c
Concentration expressed as mg AFB
1
/ml.
d
L. rhamnosus strain GG.
e
L. rhamnosus strain LC-705.
f
P. freudenreichii ssp. shermanii JS.
g
ND, below the detection limit of the HPLC method used (200 pg AFB
1
/ml methanol).
lution (Orion, Finland) containing 60 mg/ml of sodium pentobar-
bital. This dose was sufficient to keep the animal under anesthesia
for 60 min. A 2–3-cm cross-sectional cut in the lower abdominal
region was made and a 5–7-cm-long segment of the duodenum
around the pancreas was separated by two ligatures. Before tight-
ening of the second ligature the test solutions were injected into
the loop.
Chickens were divided into three groups per bacterial strain
studied (two tests and one control). For the first test group (n5
5), the dose was 0.5 ml of phosphate-buffered saline (PBS, pH
7.4) containing 1.5 mg of AFB
1
. The second test group was as-
signed to examine the ability of the bacterial strains (n55 for
each strain and time point) to bind AFB
1
in vivo; 0.1 g of lyoph-
ilized bacteria (10
10
CFU) was suspended in 0.25 ml of PBS and
injected into the duodenal loop immediately followed by an in-
jection of 0.25 ml of PBS containing 1.5 mg AFB
1
(final concen-
tration of AFB
1
was 1.5 mg/0.5 ml). The chicks were killed either
within 1 min or 60 min after injection. As controls, one group of
chicks (n55) was injected with 0.5 ml of bacterial suspension
and killed after 60 min.
In vivo stability of the AFB
1
–bacterial complex. The sta-
bility of the AFB
1
–bacterial complex formed in vitro was exam-
ined under the conditions inside the duodenum. For this purpose,
lyophilized bacteria (10
10
CFU) were suspended in 1.5 ml of PBS
containing 1.5 mg AFB
1
. The mixture was incubated at 378C for
60 min after which the suspension was centrifuged. The amount
of AFB
1
in the supernatant was quantified to verify that AFB
1
was bound to the bacteria. The bacterial pellets with the bound
AFB
1
were then resuspended in 0.5 ml of PBS and injected into
the duodenal loop of chicks (n55 per strain) that were killed 1
or 60 min after the injection. The amount of AFB
1
in both intes-
tinal tissue and the supernatant fluid of the luminal content were
quantitated as in the method of El-Nezami et al. (4), and the
amount of the AFB
1
released was calculated.
In vitro stability of AFB
1
–bacterial complex. The in vivo
stability was compared with the in vitro stability of the AFB
1
bacterial complex. In this experiment after incubation of AFB
1
with bacteria as above, the supernatant was removed and analyzed
for AFB
1
residues. The bacterial pellet was suspended in water
and adjusted to pH 5 with 0.1 M lactic acid to simulate the pH
of the loop content. The mixture was then incubated for a period
of 60 min, after which the suspension was centrifuged and the
amount of AFB
1
in the supernatant was quantitated as in El-Ne-
zami et al. (4), and the amount of AFB
1
released was calculated.
Extraction of aflatoxin. The contents of the intestinal loop
were rinsed out with 5 ml of PBS after the chicks were killed,
the intestinal contents were centrifuged (at 2,000 3gand 48C for
15 min), and the supernatant was extracted twice with 2 ml chlo-
roform. The two extracts were then pooled and evaporated to dry-
ness and the residue was reconstituted in 0.5 ml methanol. In order
to confirm that the removal of AFB
1
from the intestinal content
was a result of binding of the toxin to the bacteria, the pellet was
suspended in 2 ml chloroform, shaken vigorously, and centrifuged
at 2,000 3g. The chloroform layer was evaporated to dryness
and the residue was then suspended in 0.5 ml methanol.
The ability of the bacterial strains to influence the uptake of
AFB
1
by the intestinal tissue was also investigated. The duodenal
tissue was homogenized with 4 ml chloroform. The homogenate
was filtered, the chloroform evaporated, and the residue reconsti-
tuted in 0.5 ml methanol.
All samples were analyzed by high-performance liquid chro-
matography using the conditions described in El-Nezami et al. (4).
Statistical analysis. The Mann-Whitney test was used to test
for statistical differences for AFB
1
binding and release between
different bacterial strains.
RESULTS AND DISCUSSION
The amount of AFB
1
taken up by the intestinal tissue
in the presence of L. rhamnosus strain GG at 1 min (0.07
mg/g duodenal tissue) was less than that taken up in the
case of the positive control (0.27 mg/g duodenal tissue) (Ta-
ble 1). This indicates over 70% reduction in the uptake of
AFB
1
by the duodenal tissue when AFB
1
was injected in
the presence of L. rhamnosus strain GG. The AFB
1
uptake
by duodenal tissue was also reduced by either L. rhamnosus
strain LC-705 or P. freudenreichii ssp. shermanii JS. How-
ever, the reduction in the uptake was 37 and 63% for L.
Downloaded from http://meridian.allenpress.com/jfp/article-pdf/63/4/549/2204379/0362-028x-63_4_549.pdf by Thailand user on 12 January 2023
J. Food Prot., Vol. 63, No. 4 IN VIVO BINDING OF AFLATOXIN B
1
BY SELECTED BACTERIAL STRAINS 551
TABLE 2. Percentage of AFB
1
bound when incubated with the
bacteria either in vitro or in vivo
% AFB
1
bound 6SD when AFB
1
incubated with the bacteria either:
Bacteria
In vivo
a
1 min
incubation 60 min
incubation
In vitro,
b
60 min
incubation
L. rhamnosus
strain GG
L. rhamnosus
strain LC-705
P. freudenreichii ssp.
shermanii JS
51 62
c
36 62
c
37 61
d
92 61
c
71 62
82 61
e
80 62
77 64
22 62
a
10
10
CFU/ml bacteria was incubated with 1.5 mg AFB
1
/ml for
1 or 60 min in the duodenum of 1-week-old chicks.
b
10
10
CFU/ml bacteria was incubated with 5 mg AFB
1
/ml for 60
min at 378C and pH 7.3.
c
Strains bind significantly less AFB
1
in vivo than in vitro (P,
0.05).
d
Strains binds significantly more AFB
1
in vivo than in vitro (P
,0.05).
rhamnosus strain LC-705 and P. freudenreichii ssp. sher-
manii JS, respectively. The reduction in AFB
1
uptake by
the duodenal tissue suggests that the bacterial strains tested
in this study can reduce the amount of AFB
1
absorbed into
the duodenal tissue and hence may affect aflatoxin bio-
availability.
Hsieh and Wong (7) demonstrated that over 50% of the
dose of 0.05 mg/kg [
14
C]AFB
1
disappeared from the duo-
denal region within 60 min. In this study, 97% of the AFB
1
dose disappeared from the duodenal region (luminal fluid
and duodenal tissue) within 60 min.
L. rhamnosus strain GG decreased AFB
1
by 54% in
the soluble fraction of the luminal fluid in 1 min (Table 1).
This strain was more efficient in reducing AFB
1
content in
the luminal fluid compared to the other two strains tested
(P,0.05). Both L. rhamnosus strain LC-705 and P. freu-
denreichii ssp. shermanii JS were only able to reduce AFB
1
by 44% and 36% in the soluble fractions, respectively. It
appears that this phenomenon is the result of binding of
AFB
1
by bacteria, because the difference between the
amount of AFB
1
added and that recovered from the duo-
denal tissue and luminal contents can be accounted for by
recovery from bacterial pellets as presented in Table 1. Af-
ter 60 min incubation in the duodenal loop approximately
92, 71, and 82% of the AFB
1
dose (1.5 mg AFB
1
/ml) can
be recovered from the bacterial pellets of L. rhamnosus
strain GG, L. rhamnosus strain LC-705, and P. freudenrei-
chii ssp. shermanii JS, respectively (Table 1).
There is a significant difference between the amount
of AFB
1
recovered from the bacterial pellets when the
strains tested were incubated in vivo either for 1 or 60 min
(Table 2). When the incubation was continued for 60 min,
the binding efficiency of L. rhamnosus strain GG and P.
freudenreichii ssp. shermanii JS were significantly in-
creased. This was not the case for L. rhamnosus strain LC-
705 where no significant difference was detected between
incubations for 1 min or 60 min. The difference in binding
efficiency was not noted when these strains were incubated
in vitro (4). A reduction was noted in the efficiency of the
two Lactobacillus strains to bind AFB
1
in vivo when com-
pared to their binding efficiency in vitro (Table 2). As for
P. freudenreichii ssp. shermanii JS, the binding ability of
the bacteria was significantly enhanced when the incubation
was carried out in vivo either for 1 or 60 min when com-
pared to the in vitro binding. Such differences between in
vivo and in vitro binding are not surprising, because there
are more interfering factors at work in vivo.
In the absence of added bacteria, 3% of the AFB
1
dose
was present in the luminal contents and no residue from
tissue extracts was found after 60 min, suggesting that
AFB
1
was absorbed. No residue was present in the luminal
contents when AFB
1
was injected in combination with L.
rhamnosus strain GG, but 5 and 8% of the AFB
1
dose could
be recovered in the case of L. rhamnosus strain LC-705
and P. freudenreichii ssp. shermanii JS, respectively (Table
1). These findings indicate that the complex formed be-
tween AFB
1
and L. rhamnosus strain GG is more stable
compared to that formed with L. rhamnosus strain LC-705
and P. freudenreichii ssp. shermanii JS. The ability of the
bacteria to bind AFB
1
rapidly may result in a reduction of
AFB
1
absorption via duodenal mucosa.
The AFB
1
–bacterial complex that was incubated in
vivo (in the intestinal lumen) appeared to be more stable
than the complex incubated in vitro. For all the strains test-
ed, there was no release of AFB
1
back to the duodenal
content when the AFB
1
–bacterial complex was incubated
in the intestinal loop for 60 min. When the complex was
incubated in vitro for the same period, a release of AFB
1
back into the media was noticed with all strains tested. The
release from P. freudenreichii ssp. shermanii JS (64.4 6
0.9%) was significantly higher than that from L. rhamnosus
strain GG (13.9 64.2%) or strain LC-705 (12.0 64.4%).
This study is the first demonstration of the ability of
selected bacterial strains to bind AFB
1
under in vivo con-
ditions. The findings from this study indicate that the con-
ditions inside the duodenum enhance the ability of both L.
rhamnosus strain GG and P. freudenreichii ssp. shermanii
JS to bind AFB
1
. These conditions also improve the sta-
bility of the complex formed between the strains tested and
AFB
1
. The results show that once the bacteria bind the
AFB
1
, it is not released back into duodenal fluid. We sug-
gest that binding of AFB
1
by bacteria is a promising way
to reduce the bioavailability of AFB
1
from contaminated
feed. Development of this approach has the potential to
reduce the accumulation of AFB
1
and thus decrease its tox-
icity to both humans and animals. This approach would be
of benefit to human and animal health in developing coun-
tries where reduction of aflatoxin contamination is needed
but is limited by available resources and technology. Suc-
cessful application of this approach will not only benefit
human health but may result in increased productivity of
farm animals.
ACKNOWLEDGMENTS
The skillful assistance of Mrs. R. Hall and Mrs. D. Donohue in the
preparation and reviewing of this manuscript is gratefully acknowledged.
Downloaded from http://meridian.allenpress.com/jfp/article-pdf/63/4/549/2204379/0362-028x-63_4_549.pdf by Thailand user on 12 January 2023
J. Food Prot., Vol. 63, No. 4552 EL-NEZAMI ET AL.
We thank Food Science Australia and the Center for International Mobil-
ity, Finland for their financial support during the term of this study. As-
pects of this work are subject to a current International Patent Application
(application no. 5005/97).
REFERENCES
1. Allcroft, R., and R. B. A. Carnaghan. 1963. Groundnut toxicity: an
examination for toxin in human food products from animals fed toxic
groundnut meal. Vet. Res. 75:259–263.
2. Eaton, D. L., and E. P. Callagher. 1994. Mechanisms of aflatoxin car-
cinogenesis. Annu. Rev. Pharmacol. Toxicol. 34:135–172.
3. Ellis, W. O., J. P. Smith, and B. K. Simpson. 1991. Aflatoxins in food:
occurrence, biosynthesis, effects on organisms, detection, and meth-
ods of control. Crit. Rev. Food Sci. Nutr. 30:403–439.
4. El-Nezami, H., P. Kankaanpa¨a¨, S. Salminen, and J. Ahokas. 1998.
Ability of dairy strains of lactic acid bacteria to bind food carcino-
gens. Food Chem. Toxicol. 36:321–326.
5. El-Nezami, H., P. Kankaanpa¨a¨, S. Salminen, and J. Ahokas. 1998.
Physico-chemical alterations enhance the ability of dairy strains of
lactic acid bacteria to remove aflatoxins from contaminated media. J.
Food Prot. 61:466–468.
6. El-Nezami, H., S. Salminen, and J. Ahokas. 1996. Biologic control
of food carcinogen using Lactobacillus GG. Nutr. Today 31:41S–43S.
7. Hsieh, P. H., and J. J. Wong. 1994. Pharmacokinetics and excretion
of aflatoxins, p. 73–88. In D. L. Eaton and J. D. Groopman (ed.), The
toxicology of aflatoxins: human health, veterinary, and agricultural
significance. Academic Press, San Diego, Calif.
8. Kumagai, S. 1989. Intestinal absorption and excretion of aflatoxin in
rats. Toxicol. Appl. Pharmacol. 97:88–97.
9. Robens, J. F., and J. L. Richard. 1992. Aflatoxins in animal and human
health. Rev. Environ. Contam. Toxicol. 127:69–74.
10. Rodricks, J. V., and L. Stoloff. 1977. Aflatoxin residues from contam-
inated feed in edible tissues of food producing animals, p. 75–89. In
J. V. Rodricks, C. W. Hesseltine, and M. A. Mehlman (ed.), Myco-
toxins in human and animal health. Pathotox. Publ., Park Forest
South, Ill.
11. Virta, M., S. Lineri, P. Kankaanpa¨a¨, M. Karp, K. Peltonen, J. Nuutila,
and E. M. Lilius. 1998. Determination of complement-mediated kill-
ing of bacteria by viability staining and bioluminescence. Appl. En-
viron. Microbiol. 64:515–516.
12. Wood, G. E. 1989. Aflatoxins in domestic and imported foods and
feeds. J. Assoc. Off. Anal. Chem. 72:543–548.
Downloaded from http://meridian.allenpress.com/jfp/article-pdf/63/4/549/2204379/0362-028x-63_4_549.pdf by Thailand user on 12 January 2023
... [ [83][84][85][86][87] Abbreviations: LPS: lipopolysaccharide; HCC: hepatocellular carcinoma; BA: bile acid; DCA: deoxycholic acid; ICIs: immune checkpoint inhibitors; RCT: randomized controlled trial; HR: hazard ratio; CI: confidence index. ...
... For example, targeting aflatoxins such as hepatocarcinogen, patients treated with a multistrain probiotic (Lactobacillus and Propionibacterium spp.) had a lower urinary level of the toxins [82]. Moreover, animal studies explained that the strains are able to bind aflatoxins [83]. Indeed, we cannot forget the immunomodulant mechanism of action involving the gut-liver axis. ...
Article
Full-text available
Background: Liver cancer, particularly hepatocellular carcinoma (HCC), is a significant gastrointestinal disease with a mortality rate as high as nearly 80% within five years. The disease’s pathophysiology involves deranged immune responses and bile acid metabolism, with the gut microbiota (GM) playing a crucial role. Recent research highlights the potential of GM in influencing HCC treatment outcomes, especially regarding immune checkpoint inhibitors (ICIs). However, few patients currently benefit from ICIs due to a lack of effective response biomarkers. Aims and methods: This review aimed to explore the literature on HCC treatment issues, focusing on immune response, bile acid metabolism, and GM dysbiosis. This review included studies from PubMed, Medline, and major gastroenterology and hepatology meetings, using keywords like gut microbiota, immune system, liver cancer, and checkpoint inhibitors. Results: GM dysbiosis significantly impacts immune response and bile acid metabolism, making it a promising biomarker for ICI response. Modulating GM can enhance ICI treatment efficacy, although more research is needed to confirm its direct therapeutic benefits for HCC. Conclusions: GM dysbiosis is integral to liver cancer pathogenesis and treatment response. Its modulation offers promising therapeutic avenues for improving HCC prognosis and response to immunotherapy.
... [ [83][84][85][86][87] Abbreviations: LPS: lipopolysaccharide; HCC: hepatocellular carcinoma; BA: bile acid; DCA: deoxycholic acid; ICIs: immune checkpoint inhibitors; RCT: randomized controlled trial; HR: hazard ratio; CI: confidence index. ...
... For example, targeting aflatoxins such as hepatocarcinogen, patients treated with a multistrain probiotic (Lactobacillus and Propionibacterium spp.) had a lower urinary level of the toxins [82]. Moreover, animal studies explained that the strains are able to bind aflatoxins [83]. Indeed, we cannot forget the immunomodulant mechanism of action involving the gut-liver axis. ...
Article
Full-text available
Abstract: Background: Liver cancer, particularly hepatocellular carcinoma (HCC), is a significant gastrointestinal disease with a mortality rate as high as nearly 80% within five years. The disease’s pathophysiology involves deranged immune responses and bile acid metabolism, with the gut microbiota (GM) playing a crucial role. Recent research highlights the potential of GM in influencing HCC treatment outcomes, especially regarding immune checkpoint inhibitors (ICIs). However, few patients currently benefit from ICIs due to a lack of effective response biomarkers. Aims and methods: This review aimed to explore the literature on HCC treatment issues, focusing on immune response, bile acid metabolism, and GM dysbiosis. This review included studies from PubMed, Medline, and major gastroenterology and hepatology meetings, using keywords like gut microbiota, immune system, liver cancer, and checkpoint inhibitors. Results: GM dysbiosis significantly impacts immune response and bile acid metabolism, making it a promising biomarker for ICI response. Modulating GM can enhance ICI treatment efficacy, although more research is needed to confirm its direct therapeutic benefits for HCC. Conclusions: GM dysbiosis is integral to liver cancer pathogenesis and treatment response. Its modulation offers promising therapeutic avenues for improving HCC prognosis and response to immunotherapy. Keywords: gut microbiota; immune system; liver cancer; hepatocellular carcinoma; checkpoint inhibitors
... 21 In this setting, the antibiotic treatment led to a significant expansion of hepatic C-X-X motif receptor (CXCR)6+ NKT cells in the liver, accompanied by elevated levels of IFN-γ, suggesting that depleting gut commensal bacteria enhances the anti-tumor function of hepatic NKT cells. 21 Taken together, these findings highlight the significant impact of antibiotic-induced [89][90][91][92][93][94] modifications to gut microbiota and associated metabolites on HCC development. Contrary to the findings in animal studies, a growing body of evidence from human studies supports the notion that antibiotic treatment is an important outcome predictor in the context of immune checkpoint inhibitor (ICI) therapy. ...
... 93 Separate animal studies have established that these bacterial strains can bind aflatoxins and thus reduce their absorption. 94 This reflects the utility of probiotics in reducing the harmful effects of dietary toxins and the risk of HCC. ...
Article
Full-text available
Hepatocellular carcinoma (HCC) has been linked to the gut microbiota, with recent studies revealing the potential of gut-generated responses to influence several arms of the immune responses relevant to HCC formation. The pro- or anti-tumor effects of specific bacterial strains or gut microbiota-related metabolites, such as bile acids and short-chain fatty acids, have been highlighted in many human and animal studies. The critical role of the gut microbiota in HCC development has spurred interest in modulating the gut microbiota through dietary interventions, probiotics, and fecal microbiota transplantation as a potential strategy to improve liver cancer outcomes. Encouragingly, preclinical and clinical studies have demonstrated that modulation of the gut microbiota can ameliorate liver function, reduce inflammation, and inhibit liver tumor growth, underscoring the potential of this approach to improve HCC outcomes. As research continues to unravel the complex and dynamic mechanisms underlying the gut-liver axis, the development of safe and effective interventions to target this pathway for liver cancer prevention and treatment appears to be on the horizon, heralding a significant advance in our ongoing efforts to combat this devastating disease.
... Strong evidence from in vitro tests are available to substantiate the findings of this study but in vitro adsorption is influenced by various factors like strain and concentration of bacteria, dose of toxin, temperature, pH and hence the process is considered as fast and easily reversible (Shahin, 2007). In vivo studies with single probiotic against aflatoxin are available especially with Lactobacillus and Bifidobacterium (El-Nezami et al., 2000). ...
Article
Full-text available
Aflatoxins are produced in poultry feed by two major fungal species viz., Aspergillus flavus and Aspergillus parasiticus during hot and humid seasons. To detoxify these aflatoxins, various binders are being used in the field which are mostly synthetic compounds with possible other toxicities, the harmless beneficial probiotics are being considered as binders to neutralize the effect of aflatoxins in the feed. Bacterial organisms (probiotics) like Lactobacillus rhamnosus, Lactobacillus casei, Bacillus subtilis, Enterococcus faecium and yeast (Saccharomyces cerevisiae) were selected and their cell wall structures have been retrieved and molecular docking was performed against four types of aflatoxins namely AFB1, AFB2, AFG1 and AFG2. The results revealed that cell wall components of the chosen bacterial organisms have a good binding affinity towards four types of aflatoxins. Based on this in silico results, it is evident that the both the lipoteichoic acid (LTA) and wall teichoic acid (TA) in the cell wall of probiotic organisms is responsible for its binding against aflatoxins.
... Findings from Oluwafemi et al. (2010) reported that lactic acid bacteria will at any time remove about 31% to 46% aflatoxin B1 (AFB1) from any concentration level around 140 ng/g. El-Nezami et al. (2000) reported an average of 54% aflatoxin degradation within one minute when investigating the ability of two strains of Lactobacillus rhamnosus (GG and LC-705) and a Propionibacterium spp. to eliminate AFB1 from the intestinal luminal liquid medium of a chicken. According to Cao et al. (2011), degradation of aflatoxin was as a result of the cleavage of the difuran ring of the aflatoxin molecule by the antimicrobial products produced by the bacteria. ...
Article
Full-text available
_____________________________________________________________________________________ Abstract 'Kati' purchased from local producers in Akoko, Ondo State, Nigeria and 'Kati' produced from the laboratory were microbiologically examined for presence of microorganisms and mycotoxins. The microbial counts at the different stages of production are significantly different (p > 0.05) with values ranging from 1.00 × 10 5 to 1.16× 10 6 CFU/mL. Most predominated bacteria in commercial 'Kati' were Lactococcus lactis Lactobacillus plantarum and Lactobacillus brevis. Saccharomyces cerevisiae have the highest occurrence value of 32.6% and 55.6% in commercial 'Kati' and 'Kati produced in the laboratory. There were presence of aflatoxin B1 (18.52 µg/g), aflatoxin B2 (16.02 µg/g), aflatoxin G1 (17.84 µg/g), fumonisin B1 (4.01 µg/g) and ochratoxin A1 (0.93 µg/g) in sorghum used for commercial 'Kati' production. Likewise, presence of aflatoxin B1 (16.78µg/g), aflatoxin B2 (13.94 µg/g), aflatoxin G1 (14.89 µg/g), and aflatoxin G2 (0.04 µg/g) in sorghum used for 'Kati' in the laboratory. The presence of mycotoxin residues on the starting material (sorghum) indicated that, 'Kati' and other fermented foods from cereals need to be produced under hygienic conditions. It is therefore, imperative to take into consideration, high level of hygiene with the principle of Hazard Analysis and Critical Control Point (HACCP) at different stages of production in order to reduce microbial contamination and toxins associated with fermented foods. https://journal-of-agroalimentary.ro/admin/articole/40510Clement_Ogidi_2022_28-1-_035-045.pdf
Article
نفذت هذه الدراسة في مختبر السموم التابع لقسم التحليلات المرضية في كلية العلوم الطبية التطبيقية-جامعة كربلاء اذ هدفت هذه الدراسة الى تقييم كفاءة بكتريا Lactobacillus plantarum في تحطيم سم الزيرالينون. أوضحت نتائج العزل والتشخيص ظهور الفطر Fusarium spp. بنسبة ظهور بلغت %32 ونسبة تردد بلغت %5.33. بينت نتائج أختبار قابلية عزلات الفطرFusarium spp. على انتاج سم الزيرالينون باستعمال تقانة صفائح الكروماتوغرافيا الرقيقة (TLC) وجود 13 عزلة منتجة من أصل 18 عزلة اي بنسبة %72.22 وأظهرت نتائج الدراسة فعالية بكتريا L. plantarum في أختزال سمية سم الزيرالينون خارجياً (In vitro) اذ اختفى تألق بقعة سم الزيرالينون المعالج بالبكتريا من لوحة Thin layer chromatography عند تعريضها الى الأشعة فوق البنفسجية عند طول موجي 360 نانومتر وعززت هذه النتيجة نتائج الأختبارات الحيوية داخل جسم حيوانات الجرذ الأبيض والمعاملة بالبكتريا L. plantarum متبوعاً بسم الزيرالينون اذ كانت معايير الدم الفسيولوجية سليمة تماماً. في حين ظهرت تغايرات مرضية واضحة في معايير الدم الفسيولوجية لدى الحيوانات المعاملة بسم الزيرالينون فقط. اذ بلغت أعداد كريات الدم الحمراء في معاملة البكتريا والسم 6.66×106كرية/ملم3 كما بلغت في معاملة السم فقط 4.81×106كرية/ملم3 وكانت اعداد كريات الدم البيض في معاملة البكتريا والسم 13.18×103 ملم3 اما معاملة السم فقط 14.56×103 ملم3 وبلغت كمية مكداس الدم في معاملة البكتريا والسم %62.76 أما معاملة السم فقط فكانت %42.5.
Chapter
Probiotics have been suggested to be involved in both prevention and treatment of various human cancers. Probiotics in Anticancer Immunity is a set of volumes in the Frontiers in Cancer Immunology series that explains biochemical mechanisms of anticancer immunity exerted by probiotics in various human cancers. It presents edited chapters focused on the evidence of probiotic use against human cancers through several animal and human studies. This volume of Probiotics in Anticancer Immunity consists of 11 chapters. The introductory chapters provide information about the link between gut microbiota and the host immune system in cancer and the general mechanisms of anticancer immunity exerted by probiotics. Subsequent chapters are focused on probiotics' anticancer immunity in specific cancers such as, skin cancer, stomach cancer, breast cancer, lung cancer, head and neck cancer, liver cancer, cervical and colon cancer. Key features - Gives a new dimensions and insight in the role of probiotics in anticancer immunity towards various human cancers - Provides several color figures and tables to clearly explain relevant information - Includes recent information with new insights and references - Meets the needs of basic (pre-clinical) and advanced clinical researchers and postgraduate scholars
Chapter
Probiotics have been suggested to be involved in both prevention and treatment of various human cancers. Probiotics in Anticancer Immunity is a set of volumes in the Frontiers in Cancer Immunology series that explains biochemical mechanisms of anticancer immunity exerted by probiotics in various human cancers. It presents edited chapters focused on the evidence of probiotic use against human cancers through several animal and human studies. This volume of Probiotics in Anticancer Immunity consists of 11 chapters. The introductory chapters provide information about the link between gut microbiota and the host immune system in cancer and the general mechanisms of anticancer immunity exerted by probiotics. Subsequent chapters are focused on probiotics' anticancer immunity in specific cancers such as, skin cancer, stomach cancer, breast cancer, lung cancer, head and neck cancer, liver cancer, cervical and colon cancer. Key features - Gives a new dimensions and insight in the role of probiotics in anticancer immunity towards various human cancers - Provides several color figures and tables to clearly explain relevant information - Includes recent information with new insights and references - Meets the needs of basic (pre-clinical) and advanced clinical researchers and postgraduate scholars
Chapter
Probiotics have been suggested to be involved in both prevention and treatment of various human cancers. Probiotics in Anticancer Immunity is a set of volumes in the Frontiers in Cancer Immunology series that explains biochemical mechanisms of anticancer immunity exerted by probiotics in various human cancers. It presents edited chapters focused on the evidence of probiotic use against human cancers through several animal and human studies. This volume of Probiotics in Anticancer Immunity consists of 11 chapters. The introductory chapters provide information about the link between gut microbiota and the host immune system in cancer and the general mechanisms of anticancer immunity exerted by probiotics. Subsequent chapters are focused on probiotics' anticancer immunity in specific cancers such as, skin cancer, stomach cancer, breast cancer, lung cancer, head and neck cancer, liver cancer, cervical and colon cancer. Key features - Gives a new dimensions and insight in the role of probiotics in anticancer immunity towards various human cancers - Provides several color figures and tables to clearly explain relevant information - Includes recent information with new insights and references - Meets the needs of basic (pre-clinical) and advanced clinical researchers and postgraduate scholars
Chapter
Mycotoxins are a group of low molecular weight secondary metabolites that can lead to toxic reactions in humans and animals. These mycotoxins of importance are chiefly produced by the species of Aspergillus, Penicillium, and Fusarium, which are known to produce different types of toxins including aflatoxins, ochratoxins, citrinin, patulin, zearalenone, zearalenol, fumonisins, deoxynivalenol, and trichothecenes. Many of these toxins are heat stable and impose health risks to humans and animals, thereby causing disease syndromes known as mycotoxicoses. Several factors affect the colonization and production of mycotoxins by fungi, including pH, temperature, humidity, and substrate nutrition. They can be produced in the field, before harvest, after harvest, or during transportation and storage. It is urgently necessary to establish national guidelines for the prevention and management of mycotoxin contamination in agricultural products in India. Mycotoxin contamination of agricultural commodities leads to export rejection, which is a matter of great concern from an economic point of view. In this review, we will discuss the different types of mycotoxins, their structure, toxicological effects on human and animal health, and the various microorganisms that are capable of detoxifying them.KeywordsMycotoxins Aspergillus Penicillium Fusarium Biological detoxification
Article
Full-text available
Much progress has been made in elucidating the biochemical and molecular mechanisms that underlie aflatoxin carcinogenesis. In humans, biotransformation of AFB1 to the putative carcinogenic intermediate. AFB-8,9-exo-epoxide, occurs predominantly by cytochromes P450 1A2 and 3A4, with the relative importance of each dependent upon the relative magnitude of expression of the respective enzymes in liver. Genetic variability in the expression of these and other cytochromes P450 may result in substantial interindividual differences in susceptibility to the carcinogenic effects of aflatoxins. Detoxification of AFB-8,9-epoxide by a specific alpha class glutathione S-transferase is an important protective mechanism in mice, and it accounts for the resistance of this species to the carcinogenic effects of AFB. This particular form of GST is expressed constitutively only at low levels in rats, but it is inducible by antioxidants such as ethoxyquin, and it accounts for much of the chemoprotective effects of a variety of substances, including natural dietary components that putatively act via an "antioxidant response element" (ARE). In humans, the constitutively expressed GSTs have very little activity toward AFB1-8,9-exo-epoxide, suggesting that--on a biochemical basis--humans should be quite sensitive to the genotoxic effects of aflatoxins. If a gene encoding a high aflatoxin-active form of GST is present in the human genome, but is not constitutively expressed, and is inducible by dietary antioxidants (as occurs in rats), then chemo- and/or dietary intervention measures aimed at inducing this enzyme could be highly effective. However, as it is possible that human CYP 1A2 may also be inducible by these same chemicals (because of the possible presence of an ARE in this gene), the ultimate consequence of dietary treatment with chemicals that induce biotransformation enzymes via an ARE is uncertain. The balance of the rate of activation (exo-epoxide production) to inactivation (GST conjugation plus other P450-mediated non-epoxide oxidations) may be a strong indicator of individual and species susceptibility to aflatoxin carcinogenesis, if the experimental conditions are reflective of true dietary exposures. There is strong evidence that AFB-8,9-exo-epoxide binds to G:C rich regions of DNA, forming an adduct at the N7-position of guanine. Substantial evidence demonstrates that AFB1-8,9-epoxide can induce activating mutations in the ras oncogene in experimental animals, primarily at codon 12.(ABSTRACT TRUNCATED AT 400 WORDS)
Article
Lactobacillus GG was examined in vitro for its ability to bind food-borne carcinogens. The bacteria exhibited good binding activity toward aflatoxin B1 and moderate level of binding to aflatoxin B2 and aflatoxin G1 No significant binding activity was observed with aflatoxin G2. Binding activity was both time and concentration dependent. Heat treatment of the bacteria alter the binding activity.
Article
Although aflatoxins have been the cause of numerous deaths in livestock and suspected in some deaths of humans, the impact of aflatoxin consumption by a wide variety of animal species, including humans, extends much further than such a focal point. The economic significance of this group of toxins occurring in feeds and foods is through lowered productivity including meat and eggs, reduced weight gain, reduced feed efficiency, increased incidence of disease because of immunosuppression, and subtle damage to vital organs. Several human diseases have been recognized as being caused by aflatoxins, especially acute aflatoxicosis associated with highly contaminated foodstuffs (Shank 1977; Krishnamachari et al. 1975a, 1975b; Ngindu et al. 1982).
Article
Aflatoxins are secondary metabolites produced by species of Aspergilli, specifically Aspergillus flavus and Aspergillus parasiticus. These molds are ubiquitous in nature and grow on a variety of substrates, thereby producing aflatoxins. Aflatoxins are of great concern due to their biochemical and biological effects on living organisms. In this article, the occurrence of aflatoxins, their biosynthesis, factors influencing their production, their effects on living organisms, and methods of detection and control in food are reviewed. Future areas of research involving mathematical modeling of factors influencing aflatoxin production and alternative methods of control, such as modified atmosphere packaging, are also discussed.
Article
Aflatoxin B1 (AFB1) transfer across the gastrointestinal tract was studied in rats. The rate of biliary secretion of 3H was higher when [3H]AFB1 was injected into the small intestine than when injected into the stomach. When various sites of the small intestine were perfused with the medium containing [3H]AFB1, the highest rate of disappearance of 3H from the medium was noted in the duodenum. Also the rate of biliary secretion of 3H tended to be higher when the duodenum was perfused than when the other sites were perfused. These results suggest that AFB1 is absorbed mainly from the small intestine, most efficiently from the duodenum. Uptake of AFB1 by the everted intestine in vitro was slightly greater in the jejunum than the other sites, suggesting that the cause of the differences in the intestinal absorption among various sites may reside in the transfer process of AFB1 from the epithelial cell layer to vascular circulation. Comparison of the AFB1 appearance in the mesenteric venous plasma and lymph showed that AFB1 is absorbed almost exclusively in the vein. Distribution of 3H in the mesenteric plasma on thin-layer chromatography revealed that metabolic degradation of AFB1 takes place in the duodenal and jejunal tissues during the course of AFB1 absorption. Examination of the appearance of AFB1 or 3H in the intestinal perfusate after iv injection of of AFB1 or [3H]AFB1 suggested that AFB1 and its metabolites can transfer from the blood to the intestinal lumen. The rate of the AFB1 absorption from various sites of the intestine changed with age and reproductive stage, indicating that the AFB1 transfer across the intestinal wall is under the influence of the growth and reproductive endocrine condition.
Article
Aflatoxins, metabolic products of the molds Aspergillus flavus and A. parasiticus, may occur in foods and feeds. These toxins cannot be entirely avoided or eliminated from foods or feeds by current agronomic and manufacturing processes and are considered unavoidable contaminants. To limit aflatoxin exposure, the U.S. Food and Drug Administration (FDA) has set action levels for these toxins in foods and feeds involved in interstate commerce. FDA continually monitors food and feed industries through compliance programs. This report summarizes data generated from compliance programs on aflatoxins for the fiscal year 1986. Commodities sampled included peanuts and peanut products, corn and corn products, tree nuts, cottonseed, milk, spices, manufactured products, and miscellaneous foods and feeds. Correlations were highest between aflatoxin contamination and geographical areas for corn/corn products and cottonseed/cottonseed meal. Higher incidences of aflatoxin contamination in corn and corn products designated for human consumption were observed in samples collected in the southeastern states (32 and 28%, respectively). A higher incidence of contamination was observed in corn designated for animal feed from Arkansas-Texas (74%) than from the southeastern states (47%). Only 3% of feed corn from corn belt states contained detectable aflatoxins. All aflatoxin-contaminated cottonseed was collected in the Arizona-California area; 80% of cottonseed meal analyzed from this area also contained detectable levels of aflatoxins.(ABSTRACT TRUNCATED AT 250 WORDS)